Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.54 |
| ▸ | CA2 | P00918 | 15/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671276 | 1.00 | CA1 (0.54) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1245850 | 0.80 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL31296417 | 0.79 | CA1 (0.52) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2775483 | 0.79 | CA1 (0.52) | CA1CA2CA12CA7CA13 | |
| SCHEMBL4453156 | 0.78 | CA1 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29571087 | 0.78 | CA1 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1535900 | 0.76 | CA12 (0.38) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1799529 | 0.76 | PTGES2 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL7245664 | 0.76 | CA12 (0.38) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29671274 | 0.76 | CA12 (0.38) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631995-A2 | MANUFACTURE OF A POLYMER DEVICE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-03-08 | — | — | EP | claimed |
| WO-2004100282-A2 | MANUFACTURE OF A POLYMER DEVICE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2004-11-18 | — | — | WO | claimed |
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| US-8530269-B2 | Manufacture of a polymer device | CAMBRIDGE ENTERPRISE LTD (GB) | 2013-09-10 | — | — | US | disclosed |
| EP-1631995-B1 | MANUFACTURE OF A POLYMER DEVICE | CAMBRIDGE ENTPR LTD (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20070172978-A1 | Manufacture of a polymer device | CAMBRIDGE UNIVERSITY TECHNICAL SERVICE LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| EP-1631995-A2 | MANUFACTURE OF A POLYMER DEVICE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004100282-A2 | MANUFACTURE OF A POLYMER DEVICE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-6630513-B1 | Capable of lowering plasma cholesterol levels and inhibiting abnormal cell proliferation, such as in cervical adenocarcinoma | TULARIX INC. | 2003-10-07 | — | — | US | disclosed |
| WO-2001012593-A1 | ARYLSULFONANILIDE DERIVATIVES | TULARIK INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6153585-A | FOR TREATING CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | CA1 2665/4885CA2 2232/4885CA12 2947/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | CA1 4526/4885CA2 4102/4885CA12 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.